Babylon Health
September 1, 2021Article of the Month – September 2021
September 1, 2021Women’s Healthcare
The FDA approves innovative devices that will benefit women’s health like MobileODT colposcope, MOLLI breast cancer localization technology...
MobileODT touts colposcope-based cervical cancer detection AI
One of the leading causes of death in developing countries is cervical cancer. Cervical cancer is the fourth most common cancer in women. The first step for screening is a pap smear. If results arrive abnormal, the next step is a colposcopy to closely examine the cervix, vagina, and vulva for signs of pre-malignant or malignant lesions. However, the procedure is uncomfortable and not always available, especially in developing countries where this screening is not readily available.
MobileODT colposcope is a comfortable and accessible option other than a general colposcopy, especially in underserviced areas.
Smart mobile colposcope adopts artificial intelligence to detect precancerous lesions (cervical dysplasia) using a digital images database with accurate and cost-effective results.
One of the leading causes of death in developing countries is cervical cancer. Cervical cancer is the fourth most common cancer in women. The first step for screening is a pap smear. If results arrive abnormal, the next step is a colposcopy to closely examine the cervix, vagina, and vulva for signs of pre-malignant or malignant lesions. However, the procedure is uncomfortable and not always available, especially in developing countries where this screening is not readily available.
MobileODT colposcope is a comfortable and accessible option other than a general colposcopy, especially in underserviced areas.
Smart mobile colposcope adopts artificial intelligence to detect precancerous lesions (cervical dysplasia) using a digital images database with accurate and cost-effective results.
MobileODT builds portable, smart, connected medical devices to enable health providers to reach every patient, everywhere. It is affordable and practical for nurses, general practitioners, and training physicians, but powerful enough to be used by expert clinicians and even replace their larger and expensive devices.(1,2,3)
The EVA’s artificial intelligence algorithm will help conduct a colposcopy with more precision to identify abnormal tissue with a high probability of a future cervical cancer diagnosis.
EVA’s, is an easy-to-use software for data management, image and video capture, annotations, clinical decision-tracking, and integration into electronic medical records. Furthermore, the data is transferred to the cloud, where the algorithm will assess the image for future comparison with other images, making this resource an outstanding visualization tool.(4,5)
FDA Clearance MOLLI Wire-free Localization Technology for Breast Cancer Surgery
Molli is a new wire-free localization technology for breast cancer surgery that helps radiologists mark lesions with more precision to help surgeons localize and remove the lesions, leading to more esthetic results and a less traumatic experience for patients. This technology was cleared by the Food and Drug Administration (FDA) on May 3, 2021.
The mission of Molli technology is to help healthcare workers remove even the smallest tumors with high precision while making the patients’ journey more pleasant. Molli consists of an implantable marker that is consequently detected and visualized on a tablet providing a superior tumor localization. This technology is freely available for the whole team (radiologists and surgeons), and most importantly, its precision provides ease of use and better results compared to other methods. (Wire or radioactive seed).
Molli is a new wire-free localization technology for breast cancer surgery that helps radiologists mark lesions with more precision to help surgeons localize and remove the lesions, leading to more esthetic results and a less traumatic experience for patients. This technology was cleared by the Food and Drug Administration (FDA) on May 3, 2021. The mission of Molli technology is to help healthcare workers remove even the smallest tumors with high precision while making the patients’ journey more pleasant.
Molli consists of an implantable marker that is consequently detected and visualized on a tablet providing a superior tumor localization. This technology is freely available for the whole team (radiologists and surgeons), and most importantly, its precision provides ease of use and better results compared to other methods. (Wire or radioactive seed).
Molli uses a solid magnet technology that is non-radioactive to mark target tissue within 24 hours or up to 30 days before the surgery. Because Molli is based on magnetism and does not utilize radioactive seed to localize suspicious lesions, it eliminates any anxiety patients may have concerning radiation exposure. Furthermore, avoid time-consuming and expensive resources better adjusting to hospital protocols and radiation safety regulations. The technology provides radiologists the confidence and efficiency to utilize the benefits of easy needle insertion and compatibility with conventional mammography and ultrasound imaging. The Molli Marker is 3.2 mm in size, enabling radiologists to precisely localize the tiniest non-palpable tumors. (6,7,8)
Ava Women – AI-Powered Sensor Bracelet for Ovulation Tracking
Whether the patient is struggling to conceive or just starting on the journey to conception, Ava helps achieve women’s baby goals faster than other methods in the market. Proper timing during intercourse can double the chances of conception; unfortunately, 75% of couples get that timing wrong.
Ava Women is the first device to track the fertile days of a woman’s menstrual cycle in real-time. It helps women trying to get pregnant and women who want to track their menstruation cycle better. Such wearable devices gather the information that is further analyzed to predict the next ovulation period.
The product consists of a sensor bracelet, a smartphone app, and a backend with self-learning algorithms. The patients must wear the bracelet during nighttime to measure physiological parameters and predict the next fertile window and ovulation. These measures include pulse, breathing rate, sleep quality, and temperature. It also can be used for screening other women’s health issues.
Bloomlife – At-Home Contraction Monitor
The developing devices and technologies that allow for visualizing and tracking contractions at home is a new way of innovating in Women’s Health. Bloomlife is a wearable sensor connected with a smartphone app to provide expecting parents a comfortable way of counting contraction. Bloomlife puts clinically validated information into the hands of expecting parents, starting with a better way to visualize and track contractions.
By keeping track of contractions and measuring the frequency and intensity, patients can better understand their progress. It is not meant to be a diagnostic tool, as it cannot differentiate between Braxton Hicks’s contractions and true labor contractions. However, BloomLife provides a better understanding of a woman’s body during pregnancy, helping parents make better decisions during that confusing and high-stress time.(9,10)
Bloomlife – At-Home Contraction Monitor
The developing devices and technologies that allow for visualizing and tracking contractions at home is a new way of innovating in Women’s Health. Bloomlife is a wearable sensor connected with a smartphone app to provide expecting parents a comfortable way of counting contraction. Bloomlife puts clinically validated information into the hands of expecting parents, starting with a better way to visualize and track contractions.
By keeping track of contractions and measuring the frequency and intensity, patients can better understand their progress. It is not meant to be a diagnostic tool, as it cannot differentiate between Braxton Hicks’s contractions and true labor contractions. However, BloomLife provides a better understanding of a woman’s body during pregnancy, helping parents make better decisions during that confusing and high-stress time. (9,10)